Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.60 |
| ▸ | PPARA | Q07869 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | LSS | P48449 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3032142 | 0.92 | MAPT (0.61) | MAPTMEN1KMT2AKCNH2L3MBTL1 | |
| SCHEMBL5817865 | 0.87 | MAPK1 (0.62) | SRD5A2PPARAMAPTMEN1KMT2A | |
| Acetic Acid SCHEMBL27483981 | 0.87 | MAPT (0.59) | MAPTMEN1KMT2APOLBKCNH2 | |
| SCHEMBL38773 | 0.85 | SRD5A2 (0.63) | SRD5A2POLBMAPK1GAAL3MBTL1 | |
| SCHEMBL14699611 | 0.85 | SRD5A2 (0.52) | SRD5A2MAPTMEN1KMT2ALSS | |
| SCHEMBL4656215 | 0.84 | DRD2 (0.57) | MAPTMEN1KMT2AKCNH2L3MBTL1 | |
| SCHEMBL31410112 | 0.84 | MAPT (0.56) | MAPTMEN1KMT2AKCNH2GAA | |
| SCHEMBL4612581 | 0.83 | MAPT (0.57) | PPARAMAPTMEN1KMT2AKCNH2 | |
| SCHEMBL10737114 | 0.82 | LSS (0.57) | SRD5A2MAPTLSSKCNH2GAA | |
| SCHEMBL25190952 | 0.82 | MAOB (0.72) | MAPTMEN1KMT2ALMNAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758367-B1 | NOVEL ISOCYANATE AND ISOTHIOCYANATE COMPOUNDS FOR CANCER TREATMENT | DoubleHill GmbH (DE) | 2015-11-18 | — | — | EP | disclosed |
| US-8987316-B2 | Isocyanate and isothiocyanate compounds for cancer treatment | DoubleHill GmbH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987316-B2 | Isocyanate and isothiocyanate compounds for cancer treatment | DoubleHill GmbH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20140228419-A1 | Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment | DoubleHill GmbH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140228419-A1 | Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment | DoubleHill GmbH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-8426390-B2 | Triazene compounds for the treatment of cancer | TRIN THERAPEUTICS GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| US-8426390-B2 | Triazene compounds for the treatment of cancer | TRIN THERAPEUTICS GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| WO-2013041204-A1 | NOVEL ISOCYANATE AND ISOTHIOCYANATE COMPOUNDS FOR CANCER TREATMENT | 2LUTION GmbH (DE) | 2013-03-28 | — | — | WO | disclosed |
| EP-2557075-A1 | New triazene compounds for treating cancer | Trin Therapeutics GmbH (DE) | 2013-02-13 | — | — | EP | disclosed |
| US-20120028927-A1 | Novel Triazene Compounds For The Treatment Of Cancer | TRIN THERAPEUTICS GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028927-A1 | Novel Triazene Compounds For The Treatment Of Cancer | TRIN THERAPEUTICS GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| US-8034797-B2 | Triazene compounds for the treatment of cancer | TRIN THERAPEUTICS GMBH (DE) | 2011-10-11 | — | — | US | disclosed |
| US-8034797-B2 | Triazene compounds for the treatment of cancer | TRIN THERAPEUTICS GMBH (DE) | 2011-10-11 | — | — | US | disclosed |
| US-20100234327-A1 | Novel Triazene Compounds For The Treatment Of Cancer | TRIN PHARMA GMBH (CH) | 2010-09-16 | — | — | US | disclosed |
| US-20100234327-A1 | Novel Triazene Compounds For The Treatment Of Cancer | TRIN PHARMA GMBH (CH) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234327-A1 | Novel Triazene Compounds For The Treatment Of Cancer | KRAS, TP53, VHL | SRD5A2 3680/4885PPARA 2387/4885MAPT 1925/4885 |
| US-20140228419-A1 | Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment | IDH3A, IDH3B, IDH2 | SRD5A2 4557/4885PPARA 3425/4885MAPT 1762/4885 |
| US-20120028927-A1 | Novel Triazene Compounds For The Treatment Of Cancer | KRAS, TP53, VHL | SRD5A2 3680/4885PPARA 2387/4885MAPT 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.